These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 25155401)

  • 1. Blood neutrophil-lymphocyte ratio predicts survival in patients with advanced pancreatic cancer treated with chemotherapy.
    Luo G; Guo M; Liu Z; Xiao Z; Jin K; Long J; Liu L; Liu C; Xu J; Ni Q; Yu X
    Ann Surg Oncol; 2015 Feb; 22(2):670-6. PubMed ID: 25155401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High neutrophil-to-lymphocyte ratio persistent during first-line chemotherapy predicts poor clinical outcome in patients with advanced urothelial cancer.
    Rossi L; Santoni M; Crabb SJ; Scarpi E; Burattini L; Chau C; Bianchi E; Savini A; Burgio SL; Conti A; Conteduca V; Cascinu S; De Giorgi U
    Ann Surg Oncol; 2015 Apr; 22(4):1377-84. PubMed ID: 25234022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of baseline and change in neutrophil-to-lymphocyte ratio in predicting prognosis: a retrospective analysis in advanced pancreatic ductal adenocarcinoma.
    Chen Y; Yan H; Wang Y; Shi Y; Dai G
    Sci Rep; 2017 Apr; 7(1):753. PubMed ID: 28392554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Albumin and Neutrophil-Lymphocyte Ratio (NLR) Predict Survival in Patients With Pancreatic Adenocarcinoma Treated With SBRT.
    Alagappan M; Pollom EL; von Eyben R; Kozak MM; Aggarwal S; Poultsides GA; Koong AC; Chang DT
    Am J Clin Oncol; 2018 Mar; 41(3):242-247. PubMed ID: 26757436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postoperative Neutrophil-to-Lymphocyte Ratio as a Predictor of Long-Term Prognosis after Pancreatectomy for Pancreatic Carcinoma: A Retrospective Analysis.
    Tsujita E; Ikeda Y; Kinjo N; Yamashita YI; Hisano T; Furukawa M; Taguchi KI; Morita M; Toh Y; Okamura T
    Am Surg; 2017 Jun; 83(6):610-616. PubMed ID: 28637563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin.
    Formica V; Morelli C; Ferroni P; Nardecchia A; Tesauro M; Pellicori S; Cereda V; Russo A; Riondino S; Guadagni F; Roselli M
    Cancer Biomark; 2016 Sep; 17(3):335-345. PubMed ID: 27434293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of preoperative NLR and CA19-9 in pancreatic cancer.
    Asaoka T; Miyamoto A; Maeda S; Tsujie M; Hama N; Yamamoto K; Miyake M; Haraguchi N; Nishikawa K; Hirao M; Ikeda M; Sekimoto M; Nakamori S
    Pancreatology; 2016; 16(3):434-40. PubMed ID: 26852169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combination of systemic inflammation-based marker NLR and circulating regulatory T cells predicts the prognosis of resectable pancreatic cancer patients.
    Cheng H; Luo G; Lu Y; Jin K; Guo M; Xu J; Long J; Liu L; Yu X; Liu C
    Pancreatology; 2016; 16(6):1080-1084. PubMed ID: 27665172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of neutrophil to lymphocyte ratio in patients with advanced pancreatic ductal adenocarcinoma treated with systemic chemotherapy.
    Kitsugi K; Kawata K; Noritake H; Chida T; Ohta K; Ito J; Takatori S; Yamashita M; Hanaoka T; Umemura M; Matsumoto M; Morita Y; Takeda M; Furuhashi S; Kitajima R; Muraki R; Ida S; Matsumoto A; Suda T
    Ann Med; 2024 Dec; 56(1):2398725. PubMed ID: 39221763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Neutrophil/Lymphocyte Ratio at Diagnosis Is Significantly Associated with Survival in Metastatic Pancreatic Cancer Patients.
    Piciucchi M; Stigliano S; Archibugi L; Zerboni G; Signoretti M; Barucca V; Valente R; Fave GD; Capurso G
    Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28353661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of the pretreatment neutrophil-lymphocyte ratio as a predictor of overall survival in a cohort of patients with pancreatic ductal adenocarcinoma.
    Ben Q; An W; Wang L; Wang W; Yu L; Yuan Y
    Pancreas; 2015 Apr; 44(3):471-7. PubMed ID: 25423560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative Neutrophil-Lymphocyte and Lymphocyte-Monocyte Ratios Reflect Immune Cell Population Rearrangement in Resectable Pancreatic Cancer.
    Sierzega M; Lenart M; Rutkowska M; Surman M; Mytar B; Matyja A; Siedlar M; Kulig J
    Ann Surg Oncol; 2017 Mar; 24(3):808-815. PubMed ID: 27770341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated preoperative neutrophil-to-lymphocyte ratio as a predictor of survival after gastroenterostomy in patients with advanced pancreatic adenocarcinoma.
    Sugiura T; Uesaka K; Kanemoto H; Mizuno T; Okamura Y
    Ann Surg Oncol; 2013 Dec; 20(13):4330-7. PubMed ID: 23982254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperfibrinogen Is Associated With the Systemic Inflammatory Response and Predicts Poor Prognosis in Advanced Pancreatic Cancer.
    Qi Q; Geng Y; Sun M; Chen H; Wang P; Chen Z
    Pancreas; 2015 Aug; 44(6):977-82. PubMed ID: 25931258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment blood neutrophil/lymphocyte ratio is associated with metastasis and predicts survival in patients with pancreatic cancer.
    Guo J; Wu M; Guo L; Zuo Q
    Bull Cancer; 2018 Feb; 105(2):146-154. PubMed ID: 29290332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical implications of systemic inflammatory response markers as independent prognostic factors for advanced pancreatic cancer.
    Qi Q; Geng Y; Sun M; Wang P; Chen Z
    Pancreatology; 2015; 15(2):145-50. PubMed ID: 25641673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Combination of Neutrophil-to-lymphocyte Ratio and Serum Carbohydrate Antigen 19-9 Level as a Prognostic Indicator in Patients with Recurrent Pancreatic Cancer.
    Sakamoto T; Saito H; Uchinaka EI; Morimoto M; Amisaki M; Tokuyasu N; Honjo S; Ashida K; Fujiwara Y
    Anticancer Res; 2018 Sep; 38(9):5497-5503. PubMed ID: 30194208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of systemic inflammation-based markers in advanced pancreatic cancer.
    Martin HL; Ohara K; Kiberu A; Van Hagen T; Davidson A; Khattak MA
    Intern Med J; 2014 Jul; 44(7):676-82. PubMed ID: 24750233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy of protein-bound polysaccharide K in patients with gastric cancer undergoing chemotherapy with an oral fluoropyrimidine (S-1).
    Namikawa T; Fukudome I; Ogawa M; Munekage E; Munekage M; Shiga M; Maeda H; Kitagawa H; Kobayashi M; Hanazaki K
    Eur J Surg Oncol; 2015 Jun; 41(6):795-800. PubMed ID: 25887287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined pretreatment serum CA19-9 and neutrophil-to-lymphocyte ratio as a potential prognostic factor in metastatic pancreatic cancer patients.
    Song JY; Chen MQ; Guo JH; Lian SF; Xu BH
    Medicine (Baltimore); 2018 Jan; 97(4):e9707. PubMed ID: 29369199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.